Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cyclophosphamide + SGT-53 + Topotecan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|SGT-53||transferrin receptor-targeted liposomal p53 cDNA||p53 Gene Therapy 4||SGT-53 is a cationic liposomal complex that is linked to an antibody targeting the transferrin receptor (Tff) and contains wild-type Tp53 plasmid, thereby delivering wild-type Tp53 to tumor cells expressing Tff and potentially restoring wild-type Tp53 activity (PMID: 23470564)|
|Topotecan||Hycamtin||Topotecan Hcl||Topotecan binds to topoisomerase I and stablizes complexes with DNA, resulting in decreased repair of DNA single-strand breaks, and potentially leading to cell death (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02354547||Phase I||Cyclophosphamide + SGT-53 + Topotecan||A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors||Recruiting|